BNP Paribas Financial Markets Increases Stock Position in Caris Life Sciences, Inc. $CAI

BNP Paribas Financial Markets raised its holdings in Caris Life Sciences, Inc. (NASDAQ:CAI) by 57,052.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 685,826 shares of the company’s stock after purchasing an additional 684,626 shares during the quarter. BNP Paribas Financial Markets’ holdings in Caris Life Sciences were worth $18,504,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. UBS Group AG grew its position in Caris Life Sciences by 825.9% during the fourth quarter. UBS Group AG now owns 2,183,980 shares of the company’s stock worth $58,924,000 after buying an additional 1,948,107 shares during the period. Zevenbergen Capital Investments LLC acquired a new stake in shares of Caris Life Sciences in the fourth quarter valued at approximately $14,655,000. Seven Grand Managers LLC grew its position in shares of Caris Life Sciences by 395.1% in the fourth quarter. Seven Grand Managers LLC now owns 495,095 shares of the company’s stock valued at $13,358,000 after purchasing an additional 395,095 shares during the last quarter. DekaBank Deutsche Girozentrale acquired a new stake in shares of Caris Life Sciences in the fourth quarter valued at approximately $3,942,000. Finally, Norges Bank acquired a new stake in shares of Caris Life Sciences in the fourth quarter valued at approximately $2,976,000.

Insiders Place Their Bets

In related news, Director Jeff L. Vacirca purchased 31,050 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average price of $16.15 per share, with a total value of $501,457.50. Following the completion of the purchase, the director directly owned 49,671 shares in the company, valued at approximately $802,186.65. This trade represents a 166.75% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. 50.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on CAI shares. Piper Sandler started coverage on shares of Caris Life Sciences in a research report on Friday, April 10th. They issued a “neutral” rating and a $21.00 price target on the stock. Citigroup lowered their price target on shares of Caris Life Sciences from $35.00 to $28.00 and set a “buy” rating on the stock in a research report on Friday, May 8th. The Goldman Sachs Group began coverage on shares of Caris Life Sciences in a research note on Wednesday, April 1st. They set a “buy” rating and a $27.00 price objective on the stock. BTIG Research reduced their price objective on shares of Caris Life Sciences from $38.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, May 8th. Finally, Wall Street Zen downgraded shares of Caris Life Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Six investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $27.56.

Caris Life Sciences Stock Down 4.6%

NASDAQ:CAI opened at $16.49 on Friday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 6.52 and a current ratio of 7.05. The stock has a market capitalization of $4.66 billion and a P/E ratio of -2.17. Caris Life Sciences, Inc. has a fifty-two week low of $14.19 and a fifty-two week high of $42.50. The stock’s 50 day moving average is $17.85.

About Caris Life Sciences

Caris Life Sciences (NASDAQ: CAI) is a molecular science company focused on advancing precision medicine in oncology. The company develops and delivers comprehensive molecular profiling services designed to identify actionable biomarkers across DNA, RNA and protein modalities. Its clinical services are intended to support oncologists in treatment decision-making by matching patients to targeted therapies, immunotherapies and relevant clinical trials based on tumor biology.

Caris provides laboratory-based diagnostic testing and related interpretive reports, combining high-throughput sequencing and other molecular technologies with bioinformatic analysis.